Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases, today reported financial results for the first quarter ended March 31, 2024, and provided business highlights.

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks